Shaoliang Chen

Shaoliang Chen Shaoliang Chen
Interventional cardiologist and Vice-President, Nanjing First Hospital, Nanjing Medical University, China
 
Biography
I?m a interventional cardiologist, and also the vice-President of Nanjing First Hospital, Nanjing Medical University, and Chief Director of Cardiology Department. I have completed more than 10000 PCI cases including CTO and LM PCIs so far. Since 2002 I set up the PCI database and QCA core Lab of our center through which 8 RCT including and registry studies including LM & bifurcation lesions , CTO and AMI treatments have been completed. In 2004 I modified classical crush into DK(double kissing and double crush) crush technique which increase the final kissing inflation rate to nearly 100%. Therefore, I organized DKCRUSH serial trials which confirmed advantage of DK crush technique in term of TLR/TVR and MACE compared with classic crush, provisional and culotte stenting since 2005. My manuscript of ? A Randomized Clinical Study Comparing Double Kissing Crush With Provisional Stenting for Treatment of Coronary Bifurcation Lesions? was published in JACC (2011;57(8):914-920), and another issue ?Comparison of DK Crush Versus Culotte Stenting for Unprotected Distal Left Main Bifurcation Lesions: Results From a Multicenter, Randomized, Prospective DKCRUSH-III Study? was also published in JACC (2013:61(14):1482-8). ?Impact of the Complexity of Bifurcation Lesions Treated With Drug-Eluting Stents The DEFINITION Study? was published in JACC : Cardiovascular Interventions(2014;11(7):1266-76). Since 2012 I focused on pulmonary artery hypertension treatment. I designed the new device named as pulmonary artery denervation radiofrequency ablation catheter, which obtained 2 patents (ZL 2012 2 0594880.6; 201310103141.1). I finished 3 articles about pulmonary artery hypertension denervation, one of the manuscripts ?Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension The Single-Center, Prospective, First-in-Man PADN-1(First-in-Man Pulmonary Artery Denervation for Treatment of Pulmonary Artery Hypertension) Study? was accepted by JACC ( 2013;62(12):1092?100)
 
Research Interest
Pulmonary Arterial Hypertension
 

Relevant Conferences